WM
MCID: WLD002
MIFTS: 58

Waldenstrom Macroglobulinemia (WM) malady

Categories: Rare diseases, Neuronal diseases, Blood diseases, Immune diseases, Genetic diseases

Aliases & Classifications for Waldenstrom Macroglobulinemia

Aliases & Descriptions for Waldenstrom Macroglobulinemia:

Name: Waldenstrom Macroglobulinemia 38 50 25 52 69 25 56
Macroglobulinemia of Waldenstrom 50 25
Waldenstrom's Macroglobulinemia 25 29
Malignant Lymphoma - Lymphoplasmacytic 69
Waldenstrom's Macroglobulinaemia 50
Lymphoplasmacytic Lymphoma 50
Waldenstrom's Syndrome 50
Wm 25

Characteristics:

Orphanet epidemiological data:

56
waldenström macroglobulinemia
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/1000000 (Europe),1-9/100000 (France),1-9/1000000 (United States),1-9/1000000 (United Kingdom),1-9/1000000 (Spain),1-9/100000 (Europe); Age of onset: Elderly; Age of death: elderly;

Classifications:



External Ids:

Orphanet 56 ORPHA33226
MESH via Orphanet 43 D008258
UMLS via Orphanet 70 C0024419
ICD10 via Orphanet 34 C88.0

Summaries for Waldenstrom Macroglobulinemia

NIH Rare Diseases : 50 waldenstrom macroglobulinemia is a chronic, slow-growing lymphoproliferative disorder. it usually affects older adults and is primarily found in the bone marrow, although lymph nodes and the spleen may be involved. affected individuals have a high level of an antibody called immunoglobulin m (igm) in their blood, which can cause thickening of the blood (hyperviscosity). although some individuals initially do not have symptoms and are diagnosed from routine blood work, common symptoms may include weakness, appetite loss and weight loss. other symptoms may include peripheral neuropathy, fever, raynaud's phenomenon, and mental status changes. hyperviscosity of the blood may cause nosebleeds, headaches, dizziness, and blurring or loss of vision. the cause of the condition is not known but environmental, genetic, and viral factors have been suggested. there have been some reports of familial cases suggesting a genetic predisposition. treatment is often reserved for those with symptoms and may include various medications including corticosteroids, alkylating agents, biologic response modifiers and purine analogues. last updated: 10/1/2013

MalaCards based summary : Waldenstrom Macroglobulinemia, also known as macroglobulinemia of waldenstrom, is related to macroglobulinemia and lymphoplasmacytic lymphoma, and has symptoms including ataxia, fatigue and fever. An important gene associated with Waldenstrom Macroglobulinemia is MYD88 (Myeloid Differentiation Primary Response 88), and among its related pathways/superpathways are Akt Signaling and NF-KappaB Family Pathway. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and lymph node, and related phenotypes are hematopoietic system and immune system

Related Diseases for Waldenstrom Macroglobulinemia

Diseases in the Waldenstrom Macroglobulinemia family:

Macroglobulinemia, Waldenstrom 2 Macroglobulinemia, Waldenstrom 1

Diseases related to Waldenstrom Macroglobulinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 68)
id Related Disease Score Top Affiliating Genes
1 macroglobulinemia 11.6
2 lymphoplasmacytic lymphoma 11.6
3 macroglobulinemia, waldenstrom 1 11.4
4 mu chain disease 10.3 CD40LG MYD88
5 colonic benign neoplasm 10.2 CD40LG MYD88
6 lymphoma 10.2
7 akinetopsia 10.2 CD40LG MYD88
8 microcystic adenoma 10.2 CD40LG MYD88
9 chondrodysplasia punctata, tibia-metacarpal type 10.2 CD40LG IGHM
10 islet cell tumor 10.2 CXCR4 PAX5
11 venezuelan equine encephalitis 10.1 CD40LG ITGAE
12 basal ganglia disease 10.1 CD40LG PAX5
13 dentin caries 10.1 CD40LG MYD88
14 neuropathy, hereditary thermosensitive 10.1 CD40LG ZAP70
15 anthracosis 10.1 CD40LG HAS1
16 arteriosclerosis 10.1 CD40LG CXCR4 MYD88
17 ectopic thymus 10.1 CD40LG ZAP70
18 mixed malaria 10.1 CD40LG MYD88
19 multiple myeloma 10.1
20 hyperparathyroidism, primary, caused by water clear cell hyperplasia 10.1 CD40 CD40LG
21 childhood brain stem glioma 10.1 PAX5 ZAP70
22 sclerosing breast papilloma 10.1 CD40 CD40LG
23 bursitis 10.1 CD40 CD40LG
24 rhabdomyosarcoma 10.1 CXCR4 MYD88 PAX5
25 immunoglobulin beta deficiency 10.1 CD40 CD40LG
26 epileptic encephalopathy, early infantile, 33 10.1 CD40 CD40LG
27 systemic mastocytosis 10.0 ITGAE PAX5
28 hypoparathyroidism, x-linked 10.0 CD40 CD40LG
29 temtamy syndrome 10.0 CD40 CD40LG
30 primary tubular proximal acidosis 10.0 IGHM MYD88 PAX5
31 bulbospinal polio 10.0 CD40 CD40LG
32 paramyloidosis 9.9 CD40LG CXCR4 MYD88 PAX5
33 retinitis 9.9
34 leukemia 9.9
35 hallucinogen dependence 9.9 CD40 CD40LG MYD88
36 somatostatinoma 9.9 CD40 ITGAE
37 carotenemia 9.9 CD40LG ITGAE
38 tall cell variant papillary carcinoma 9.9 CD40 CD40LG
39 cutis laxa, autosomal recessive, type ib 9.9 CD40 CD40LG CXCR4
40 ritscher-schinzel syndrome 9.9 CD40 CD40LG PAX5
41 brain germinoma 9.9 CD40 CD40LG
42 pulmonary fibrosis, idiopathic 9.8 CD40 CXCR4 PAX5
43 retinal vein occlusion 9.8
44 amyloidosis 9.8
45 sinusitis 9.8
46 eosinophilic colitis 9.8
47 hodgkin lymphoma 9.8
48 colitis 9.8
49 protein-losing enteropathy 9.8
50 poems syndrome 9.8

Comorbidity relations with Waldenstrom Macroglobulinemia via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease Neutropenia

Graphical network of the top 20 diseases related to Waldenstrom Macroglobulinemia:



Diseases related to Waldenstrom Macroglobulinemia

Symptoms & Phenotypes for Waldenstrom Macroglobulinemia

Human phenotypes related to Waldenstrom Macroglobulinemia:

56 32 (show all 45)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ataxia 56 32 Occasional (29-5%) HP:0001251
2 fatigue 56 32 Occasional (29-5%) HP:0012378
3 fever 56 32 Occasional (29-5%) HP:0001945
4 vertigo 56 32 Frequent (79-30%) HP:0002321
5 reduced consciousness/confusion 56 32 Occasional (29-5%) HP:0004372
6 diarrhea 56 32 Occasional (29-5%) HP:0002014
7 periorbital edema 56 32 Occasional (29-5%) HP:0100539
8 respiratory insufficiency 56 32 Frequent (79-30%) HP:0002093
9 hearing impairment 56 32 Occasional (29-5%) HP:0000365
10 splenomegaly 56 32 Occasional (29-5%) HP:0001744
11 hepatomegaly 56 32 Occasional (29-5%) HP:0002240
12 malabsorption 56 32 Occasional (29-5%) HP:0002024
13 renal insufficiency 56 32 Occasional (29-5%) HP:0000083
14 cranial nerve paralysis 56 32 Occasional (29-5%) HP:0006824
15 hypercoagulability 56 32 Frequent (79-30%) HP:0100724
16 pallor 56 32 Frequent (79-30%) HP:0000980
17 peripheral neuropathy 56 32 Occasional (29-5%) HP:0009830
18 congestive heart failure 56 32 Occasional (29-5%) HP:0001635
19 anorexia 56 32 Occasional (29-5%) HP:0002039
20 migraine 56 32 Occasional (29-5%) HP:0002076
21 memory impairment 56 32 Occasional (29-5%) HP:0002354
22 abnormality of the retinal vasculature 56 32 Occasional (29-5%) HP:0008046
23 purpura 56 32 Occasional (29-5%) HP:0000979
24 gastrointestinal hemorrhage 56 32 Occasional (29-5%) HP:0002239
25 recurrent infections 56 32 Occasional (29-5%) HP:0002719
26 epistaxis 56 32 Occasional (29-5%) HP:0000421
27 gingival bleeding 56 32 Frequent (79-30%) HP:0000225
28 urticaria 56 32 Occasional (29-5%) HP:0001025
29 vasculitis 56 32 Occasional (29-5%) HP:0002633
30 lymphoma 56 32 Very frequent (99-80%) HP:0002665
31 stroke 56 32 Occasional (29-5%) HP:0001297
32 proptosis 56 32 Occasional (29-5%) HP:0000520
33 abnormality of neutrophils 56 32 Frequent (79-30%) HP:0001874
34 lymphadenopathy 56 32 Occasional (29-5%) HP:0002716
35 cutis marmorata 56 32 Occasional (29-5%) HP:0000965
36 edema of the lower limbs 56 32 Occasional (29-5%) HP:0010741
37 retinal hemorrhage 56 32 Occasional (29-5%) HP:0000573
38 pleural effusion 56 32 Occasional (29-5%) HP:0002202
39 pulmonary infiltrates 56 32 Occasional (29-5%) HP:0002113
40 elevated erythrocyte sedimentation rate 56 32 Occasional (29-5%) HP:0003565
41 normocytic anemia 56 32 Frequent (79-30%) HP:0001897
42 leukemia 56 32 Very frequent (99-80%) HP:0001909
43 waldenstrom macroglobulinemia 56 32 Very frequent (99-80%) HP:0005508
44 multifocal epileptiform discharges 56 32 Occasional (29-5%) HP:0010841
45 cryoglobulinemia 56 32 Occasional (29-5%) HP:0100778

MGI Mouse Phenotypes related to Waldenstrom Macroglobulinemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 MYD88 PAX5 ZAP70 CD40 CD40LG CXCR4
2 immune system MP:0005387 9.5 CD40 CD40LG CXCR4 ITGAE MYD88 PAX5
3 skeleton MP:0005390 9.1 CD40 CD40LG CXCR4 MYD88 PAX5 ZAP70

Drugs & Therapeutics for Waldenstrom Macroglobulinemia

Drugs for Waldenstrom Macroglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 369)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
3
Thiotepa Approved Phase 4,Phase 2,Phase 3 52-24-4 5453
4
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 179324-69-7 387447 93860
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
6
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
7
Cytarabine Approved, Investigational Phase 4,Phase 1,Phase 2 147-94-4 6253
8
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 33419-42-0 36462
9
Methotrexate Approved Phase 4,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
10
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 1 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-24-8 5755
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
14
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
15 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
17 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
21 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
24 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1
25 Dexamethasone 21-phosphate Phase 4,Phase 3,Phase 2,Phase 1
26 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
27 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
28 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
30 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
34
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
35 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 Angiogenesis Inhibitors Phase 4,Phase 1,Phase 2
37 Angiogenesis Modulating Agents Phase 4,Phase 1,Phase 2
38 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
40 Antibodies Phase 4,Phase 2,Phase 1,Early Phase 1
41 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
42 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
43 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Folic Acid Antagonists Phase 4,Phase 2,Phase 1,Early Phase 1
45 Immunoglobulins Phase 4,Phase 2,Phase 1,Early Phase 1
46 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 1,Early Phase 1
47 Protective Agents Phase 4,Phase 2,Phase 1
48 Vitamin B Complex Phase 4,Phase 2,Phase 1,Early Phase 1
49 Methylprednisolone acetate Phase 4,Phase 2,Phase 1
50 Methylprednisolone Hemisuccinate Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 451)
id Name Status NCT ID Phase
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
2 The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia Recruiting NCT02844322 Phase 4
3 Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia Recruiting NCT02844361 Phase 4
4 The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM Recruiting NCT02844309 Phase 4
5 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4
6 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
7 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
8 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
9 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3
10 Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma Completed NCT00608374 Phase 3
11 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3
12 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
13 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3
14 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
15 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
16 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
17 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
18 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
19 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
20 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3
21 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
22 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
23 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
24 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
25 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
26 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
27 A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Recruiting NCT03053440 Phase 3
28 Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia Recruiting NCT01788020 Phase 3
29 Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3
30 Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Active, not recruiting NCT02165397 Phase 3
31 A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneo Active, not recruiting NCT01461928 Phase 3
32 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Active, not recruiting NCT00801281 Phase 3
33 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Active, not recruiting NCT01231412 Phase 3
34 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3
35 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732926 Phase 3
36 Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732913 Phase 3
37 A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia Unknown status NCT01142011 Phase 2
38 Beta Alethine in Treating Patients With Waldenstrom's Macroglobulinemia Unknown status NCT00041379 Phase 1, Phase 2
39 Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia Unknown status NCT01046006 Phase 2
40 Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia Unknown status NCT00003512 Phase 2
41 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2
42 Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Unknown status NCT01044745 Phase 2
43 Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy Unknown status NCT01035463 Phase 1, Phase 2
44 Comparison of Fludarabine Plus Total-Body Irradiation With Combination Chemotherapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Unknown status NCT00041288 Phase 2
45 Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma Unknown status NCT00937183 Phase 1, Phase 2
46 Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers Unknown status NCT00003163 Phase 2
47 Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma Unknown status NCT00397800 Phase 1, Phase 2
48 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2
49 Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia Unknown status NCT01016990 Phase 2
50 Sildenafil Citrate in Waldenstrom's Macroglobulinemia Completed NCT00165295 Phase 2

Search NIH Clinical Center for Waldenstrom Macroglobulinemia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Waldenstrom Macroglobulinemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Waldenstrom Macroglobulinemia:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Waldenstrom Macroglobulinemia:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Genetic Tests for Waldenstrom Macroglobulinemia

Genetic tests related to Waldenstrom Macroglobulinemia:

id Genetic test Affiliating Genes
1 Waldenstrom Macroglobulinemia 29

Anatomical Context for Waldenstrom Macroglobulinemia

MalaCards organs/tissues related to Waldenstrom Macroglobulinemia:

39
Bone, Bone Marrow, Lymph Node, Spleen, B Cells, Heart, Neutrophil

Publications for Waldenstrom Macroglobulinemia

Articles related to Waldenstrom Macroglobulinemia:

(show top 50) (show all 129)
id Title Authors Year
1
UNUSUAL SEROUS RETINAL DETACHMENT IN A PATIENT WITH WALDENSTROM MACROGLOBULINEMIA: A CASE REPORT. ( 28106626 )
2017
2
Waldenstrom macroglobulinemia presenting as a bilateral subdural chronic hematoma. ( 28262409 )
2017
3
Prospective, multicenter clinical trial of everolimus as primary therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). ( 27836860 )
2016
4
Learning from Waldenstrom Macroglobulinemia. ( 27825458 )
2016
5
Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection. ( 26942591 )
2016
6
A 44-Year-Old Man with Waldenstrom Macroglobulinemia and Bilateral Maxillary Sinusitis. ( 27840358 )
2016
7
Novel therapeutic targets in Waldenstrom macroglobulinemia. ( 27825468 )
2016
8
Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment. ( 27696269 )
2016
9
Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells. ( 27813535 )
2016
10
Waldenstrom macroglobulinemia: prognosis and management. ( 26849012 )
2016
11
Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas. ( 27722129 )
2016
12
Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia. ( 27268124 )
2016
13
Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. ( 26139427 )
2015
14
Waldenstrom Macroglobulinemia Mimicking Temporal Arteritis. ( 25996301 )
2015
15
Waldenstrom macroglobulinemia: prognosis and management. ( 25815903 )
2015
16
Cyclophosphamide, bortezomib and dexamethasone (CyBorD) combination in Waldenstrom Macroglobulinemia. ( 25703132 )
2015
17
Characteristic OCT Pattern in Waldenstrom Macroglobulinemia. ( 25871872 )
2015
18
Characterization of subpopulation lacking both B-cell and plasma cell markers in Waldenstrom macroglobulinemia cell line. ( 24189269 )
2014
19
Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. ( 24716234 )
2014
20
MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia. ( 24622324 )
2014
21
Waldenstrom macroglobulinemia: genetics dictates clinical course. ( 24786453 )
2014
22
Detection of erythrocytes in patients with Waldenstrom macroglobulinemia using atomic force microscopy. ( 24675428 )
2014
23
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. ( 24553177 )
2014
24
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib. ( 25060991 )
2014
25
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). ( 24004667 )
2013
26
A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia. ( 23773449 )
2013
27
MYD88 L265P mutation in Waldenstrom macroglobulinemia. ( 23532735 )
2013
28
Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia. ( 23861223 )
2013
29
Waldenstrom macroglobulinemia presenting as isolated persistent epistaxis: a very rare presentation. ( 24427564 )
2013
30
Waldenstrom macroglobulinemia presenting with pancreatic mass: a case report and review of literature. ( 23306344 )
2013
31
Nuclear protein dysregulation in lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia. ( 23355206 )
2013
32
Choice of therapy for patients with Waldenstrom macroglobulinemia. ( 23233705 )
2013
33
A new era for Waldenstrom macroglobulinemia: MYD88 L265P. ( 23723443 )
2013
34
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. ( 21732338 )
2012
35
Are you sure this is Waldenstrom macroglobulinemia? ( 23233639 )
2012
36
Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. ( 22139816 )
2012
37
Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia. ( 23048077 )
2012
38
IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia. ( 22976953 )
2012
39
Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary study. ( 22099500 )
2012
40
Progression in smoldering Waldenstrom macroglobulinemia: long-term results. ( 22451426 )
2012
41
Second malignancies among Waldenstrom macroglobulinemia patients: small samples and sparse data. ( 22100692 )
2012
42
Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia. ( 22896002 )
2012
43
Concomitant Waldenstrom macroglobulinemia and IgA plasmablastic myeloma in a patient with untreated IgM paraproteinemia: sequential development of biclonal B-cell neoplasms over a 10-year period in a single individual. ( 22404949 )
2012
44
Waldenstrom macroglobulinemia with a durable clinical response to epoetin beta. ( 22260157 )
2012
45
A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia. ( 22879385 )
2012
46
Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors. ( 21864041 )
2011
47
The bone marrow microenvironment in waldenstrom macroglobulinemia. ( 23556094 )
2011
48
Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia. ( 21393333 )
2011
49
FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation. ( 21521775 )
2011
50
Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. ( 21921047 )
2011

Variations for Waldenstrom Macroglobulinemia

Expression for Waldenstrom Macroglobulinemia

Search GEO for disease gene expression data for Waldenstrom Macroglobulinemia.

Pathways for Waldenstrom Macroglobulinemia

GO Terms for Waldenstrom Macroglobulinemia

Cellular components related to Waldenstrom Macroglobulinemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.56 CD40 CD40LG CXCR4 HAS1 IGHM ITGAE
2 cell surface GO:0009986 9.46 CD40 CD40LG CXCR4 IGHM
3 external side of plasma membrane GO:0009897 8.92 CD40 CD40LG IGHM ITGAE

Biological processes related to Waldenstrom Macroglobulinemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.61 CD40 MYD88 ZAP70
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.43 CD40 CD40LG MYD88
3 B cell proliferation GO:0042100 9.4 CD40 CD40LG
4 B cell activation GO:0042113 9.37 CD40 ZAP70
5 positive regulation of interleukin-12 production GO:0032735 9.32 CD40 CD40LG
6 inflammatory response GO:0006954 9.26 CD40 CD40LG CXCR4 MYD88
7 positive regulation of endothelial cell apoptotic process GO:2000353 9.16 CD40 CD40LG
8 regulation of immunoglobulin secretion GO:0051023 8.62 CD40 CD40LG

Sources for Waldenstrom Macroglobulinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....